stockrow
Friday 6 November 2026
Export XCUR’s income statement to Excel — free account
Exicure, Inc.
XCUR Healthcare Biotechnology
Exicure, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $500,000.00, down 98.3% from fiscal 2022.
- EPS
- +56.1%
- Free cash flow
- +65.4%
Quarter to June 2026, against a year earlier
0.91
0.02
+2.25%
Follow XCUR
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (168.37%) | (145.16%) | (92.47%) | (217.87%) |
+8 more TTM periods Free account |
|
| (54.98%) | (58.53%) | (34.00%) | (71.27%) | ||
ROIC |
0.00% | 0.00% | (1,469.79%) | (237.72%) | |
Return on Tangible Assets |
496.05% | 1,379.97% | (474.66%) | (288.68%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.05) | (1.27) | (1.24) | (1.22) | |
Free Cash Flow |
(6.70) | (8.10) | (7.80) | (7.71) | |
Capital Expenditures |
— | — | 0.75 | 0.54 | |
| Other line items | |||||
Cash ROIC |
(248.85%) | (172.25%) | (101.71%) | (67.72%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | |
Interest Coverage |
— | — | — | (797.17) | |
Operating CF/Net income |
0.81 | 0.83 | 1.73 | 0.89 | |
Depreciation/Fixed assets |
2.08 | 2.09 | 1.50 | 0.98 | |
Capex/Depreciation |
0.00 | 0.00 | 1.63 | 1.05 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.05) | (1.27) | (1.36) | (1.31) | |
Capex per Share |
0.00 | 0.00 | 0.12 | 0.09 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026